Recombinant Human Anti-CD3 x Human Anti-MET Bispecific Antibody (Tandem scFv-Fc) (BSFVF-H250)

Recombinant Anti-CD3 x Anti-MET Bispecific Antibody (Tandem scFv-Fc) is designed to be expressed as a homodimer, which has 2+2 antigen-binding valency. This format consists of one Fc region and two tandem scFv fragments, in which the anti-CD3/MET tandem scFv is fused to the Fc domain. The engineered fragment format is used to extend the half-life. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & MET

Type

Constant Domain-extended Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Solid tumors

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

MET

Gene ID

4233

UniProt ID

A0A024R759

Alternative Names

MET; MET proto-oncogene, receptor tyrosine kinase; HGFR; AUTS9; RCCP2; c-Met; hepatocyte growth factor receptor; SF receptor; HGF receptor; HGF/SF receptor; proto-oncogene c-Met; scatter factor receptor; tyrosine-protein kinase Met; met proto-oncogene tyrosine kinase

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD3 x Human Anti-MET Bispecific Antibody (Tandem scFv-Fc) (BSFVF-H250). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD3 x Human Anti-MET Bispecific Antibody (Tandem scFv-Fc) (CAT#: BSFVF-H250)

Specifications

Targets

Customer Reviews and Q&As